CVRx Announces Key Senior Leadership Team Hires
16 Maio 2024 - 8:30AM
CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical
device company, today announced three additions to its senior
leadership team. Philip B. Adamson, MD, MSc, FACC, FESC, FRCP (Ed)
has been appointed as Chief Medical Officer, Bonnie Handke, RN, MBA
will assume the role of Senior Vice President of Patient Access,
Reimbursement, and Healthcare Economics, and Jennifer E. Englund
recently joined as Senior Vice President of Global Clinical
Affairs. These roles will focus on driving the adoption of the
company's Barostim™ therapy and expanding patient access.
"We are thrilled to welcome Dr. Adamson, Bonnie, and Jennifer to
the CVRx leadership team. These three executives will play an
important role as we seek to move our Barostim therapy towards
standard of care," said Kevin Hykes, President and CEO of CVRx.
"Dr. Adamson's deep expertise and relationships within the clinical
community will be invaluable as we seek to drive awareness and
appropriate adoption among clinicians. Bonnie's extensive
experience in developing and executing market access strategies
will be central in our efforts to expand patient access and secure
favorable reimbursement. Jennifer's proven track record in leading
successful clinical evidence generation strategies will be
instrumental in further validating the efficacy of Barostim and
supporting our pursuit of expanded indications.”
As Chief Medical Officer, Dr. Adamson will spearhead efforts to
drive awareness and appropriate use of Barostim therapy among
clinicians. He will guide comprehensive medical education, outreach
and guideline integration initiatives to establish Barostim as the
standard of care for patients with heart failure. Dr. Adamson joins
CVRx from Abbott Laboratories, where he serves as Divisional Vice
President and Chief Medical Officer of the Heart Failure division.
A renowned expert in heart failure, he has nearly three decades of
experience in academia as a professor and as a practicing
cardiologist, during which time he authored over 150 manuscripts
and book chapters. Dr. Adamson earned his MD with distinction from
the University of Oklahoma College of Medicine and MSc in
physiology from the University of Oklahoma. He will begin his
employment at CVRx on May 23, 2024.
As Senior Vice President of Patient Access, Reimbursement, and
Healthcare Economics, Bonnie Handke, RN, MBA, will lead CVRx's
efforts to expand access to Barostim therapy. She is coming to CVRx
from Medtronic, which she joined over 25 years ago as a Senior
Manager in Neuromodulation and steadily progressed through roles of
increasing responsibility, most recently serving as Vice President
of Global Healthcare Economics, Policy and Reimbursement for the
Cardiovascular portfolio. Handke has a proven track record of
developing and executing market access strategies for numerous
novel therapies, successfully navigating complex reimbursement
landscapes. Handke earned an MBA from St. Thomas University, a BA
from Concordia University, and an AS in Nursing from Normandale
Community College. Bonnie will begin her new role on May 28,
2024.
Jennifer Englund joined CVRx as Senior Vice President of Global
Clinical Affairs on May 1, 2024, overseeing the development and
execution of the company's clinical evidence generation strategy,
including designing and optimizing a pipeline of post-market
studies. Englund brings over 25 years of experience in the medical
device industry, most recently serving as Senior Vice President,
Scientific Affairs at Monteris Medical, where she established a
strong clinical portfolio that was pivotal in achieving
reimbursement and clinical guideline status. She has also held
clinical leadership roles at POPS! Diabetes Care, Mardil Medical,
and Catheter Robotics. Englund holds a BS in Biology and BA in
Psychology from the University of Minnesota.
About CVRx, Inc.
CVRx is focused on the development and commercialization of the
Barostim™ System, the first medical technology approved by FDA that
uses neuromodulation to improve the symptoms of heart failure.
Barostim is an implantable device that delivers electrical pulses
to baroreceptors located in the wall of the carotid artery.
Baroreceptors activate the body's baroreflex, which in turn
triggers an autonomic response to the heart. The therapy is
designed to restore balance to the autonomic nervous system and
thereby reduce the symptoms of heart failure. Barostim received the
FDA Breakthrough Device designation and is FDA-approved for use in
heart failure patients in the U.S. It has also received the CE Mark
for heart failure and resistant hypertension in the European
Economic Area. To learn more about Barostim, visit
www.cvrx.com.
Investor Contact:
Mark Klausner or Mike VallieICR
Westwicke443-213-0501ir@cvrx.com
Media Contact:
Laura O’NeillFinn
Partners402-499-8203laura.oneill@finnpartners.com
CVRx (NASDAQ:CVRX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
CVRx (NASDAQ:CVRX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024